CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects

被引：24

作者：

Ohara, K ^{[1
]}

Tanabu, S ^{[1
]}

Ishibashi, K ^{[1
]}

Ikemoto, K ^{[1
]}

Yoshida, K ^{[1
]}

Shibuya, H ^{[1
]}

机构：

[1] Natl Minami Hanamaki Hosp, Clin Res Inst, Hanamaki 0250033, Japan

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2003年 / 58卷 / 10期

关键词：

fluvoxamine; CYP2D6; *10 allele;

D O I：

10.1007/s00228-002-0529-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective: The purpose of the present study was to investigate whether plasma fluvoxamine (FV) concentration is associated with CYP2D6*10 allele polymorphisms. Methods: Subjects were 46 Japanese patients (21 males) carrying neither *3, *4 nor *5 alleles and treated orally using FV. Venous blood was obtained from each patient for determination of FV concentration/dose (C/D) ratio (plasma concentration of FV divided by daily dose of FV per body weight) and CYP2136 genotyping. Results: No significant differences in FV C/D ratio were found between subjects with no (n=13), one (n=18) or two (n=15) *10 alleles. Conclusion: Our results indicate that CYP2D6*10 genotypes do not exert significant effects on FV C/D ratio. As CYP2136 genotypes differ with ethnic background, further studies should be conducted in different populations.

引用

页码：659 / 661

页数：3

共 20 条

[11] Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population [J].

Roh, HK ;

Dahl, ML ;

Johansson, I ;

IngelmanSundberg, M ;

Cha, YN ;

Bertilsson, L .

PHARMACOGENETICS, 1996, 6 (05) :441-447

[12] Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients [J].

Roh, HK ;

Kim, CE ;

Chung, WG ;

Park, CS ;

Svensson, JO ;

Bertilsson, L .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (09) :671-675

[13] Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients [J].

Roh, HK ;

Chung, JY ;

Oh, DY ;

Park, CS ;

Svensson, JO ;

Dahl, ML ;

Bertilsson, L .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (03) :265-271

[14]

Sachse C, 1997, AM J HUM GENET, V60, P284

[15] Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes [J].

Senda, C ;

Yamaura, Y ;

Kobayashi, K ;

Fujii, H ;

Minami, H ;

Sasaki, Y ;

Igarashi, T ;

Chiba, K .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (01) :100-103

[16] Genetic association between cytochrome P-450 2D6 gene polymorphism and plasma concentration of haloperidol in Japanese schizophrenics [J].

Shibata, N ;

Ohnuma, T ;

Baba, H ;

Shimada, H ;

Takahashi, T ;

Arai, H .

PSYCHIATRIC GENETICS, 1999, 9 (03) :145-148

[17] The major fluvoxamine metabolite in urine is formed by CYP2D6 [J].

Spigset, O ;

Axelsson, S ;

Norström, Å ;

Hägg, S ;

Dahlqvist, R .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (09) :653-658

[18] Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms [J].

Spigset, O ;

Granberg, K ;

Hagg, S ;

Norstrom, A ;

Dahlqvist, R .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (02) :129-133

[19] DETECTION OF THE POOR METABOLIZER-ASSOCIATED CYP2D6(D) GENE DELETION ALLELE BY LONG-PCR TECHNOLOGY [J].

STEEN, VM ;

ANDREASSEN, OA ;

DALY, AK ;

TEFRE, T ;

BORRESEN, AL ;

IDLE, JR ;

GULBRANDSEN, AK .

PHARMACOGENETICS, 1995, 5 (04) :215-223

[20] FLUVOXAMINE - AN UPDATED REVIEW OF ITS PHARMACOLOGY, AND THERAPEUTIC USE IN DEPRESSIVE-ILLNESS [J].

WILDE, MI ;

PLOSKER, GL ;

BENFIELD, P .

DRUGS, 1993, 46 (05) :895-924

← 1 2 →